Halozyme Therapeutics traded at $70.98 this Friday February 20th, decreasing $1.06 or 1.47 percent since the previous trading session. Looking back, over the last four weeks, Halozyme Therapeutics lost 1.02 percent. Over the last 12 months, its price rose by 22.91 percent. Looking ahead, we forecast Halozyme Therapeutics to be priced at 68.78 by the end of this quarter and at 62.58 in one year, according to Trading Economics global macro models projections and analysts expectations.
Halozyme Therapeutics, Inc. is a biopharma technology platform company. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine its ENHANZE drug delivery technology with the collaborators' compounds. The Company's lead enzyme, rHuPH20, is used to facilitate the delivery of injected drugs and fluids. The Company's approved product and its collaborators’ approved products and product candidates are based on rHuPH20, a patented recombinant human hyaluronidase enzyme. The Company's lead product, Hylenex recombinant, is a formulation of rHuPH20 that facilitates subcutaneous fluid administration for achieving hydration, to increase the dispersion and absorption of other injected drugs and, in subcutaneous urography, to improve resorption of radiopaque agents. Its pipeline products include Herceptin SC, HYQVIA, DARZALEX and others.